CG Oncology (CGON) Change in Receivables (2024 - 2026)
CG Oncology (CGON) reported Change in Receivables of $587000.0 for Q1 2026, up 234.63% on a YoY basis from $175416.0 in Q1 2025, and up 95.02% quarter-over-quarter from $301000.0 in Q4 2025.
CG Oncology (CGON) Change in Receivables (2024 - 2026) Analysis & Trends
CG Oncology has reported Change in Receivables for 3 years, with the latest figure at $587000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 234.63% year-over-year to $587000.0; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (changed N/A YoY), and the FY2025 full-year result was $320000.0, down 53.56% from the prior year.
- Change in Receivables for Q1 2026 stood at $587000.0, up from $301000.0 in the prior quarter.
- The five-year high for Change in Receivables was $644000.0 in Q4 2024, with the low at -$436000.0 in Q1 2025.
- Historically, Change in Receivables has averaged $215142.9 across 3 years, with a median of $238000.0 in 2025.
- The largest YoY upside for Change in Receivables was 628.89% in 2025 against a maximum downside of 53.26% in 2025.
- CG Oncology's Change in Receivables stood at $644000.0 in 2024, then plunged by 53.26% to $301000.0 in 2025, then jumped by 95.02% to $587000.0 in 2026.
- The last three Change in Receivables figures came in at $587000.0 (Q1 2026), $301000.0 (Q4 2025), and $238000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | CG Oncology | 5.16 Bn | 5.16 Bn | -1.88 Mn | 587,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 587,000.00 |
| Mar 31, 2026 | 587,000.00 |
| Dec 31, 2025 | 301,000.00 |
| Dec 31, 2025 | 301,000.00 |
| Sep 30, 2025 | 238,000.00 |
| Sep 30, 2025 | 238,000.00 |
| Jun 30, 2025 | 217,000.00 |
| Jun 30, 2025 | 217,000.00 |
| Mar 31, 2025 | -436,000.00 |
| Mar 31, 2025 | -436,000.00 |
| Dec 31, 2024 | 644,000.00 |
| Dec 31, 2024 | 644,000.00 |
| Sep 30, 2024 | -45,000.00 |
| Sep 30, 2024 | -45,000.00 |